- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Leap Therapeutics Inc.
Headquarters: Cambridge, MA, United States
Website: https://www.leaptx.com/
Year Founded: 2011
Status: Public
Industry Sector: HealthTechnology
CEO: Doug E. Onsi
Number Of Employees: 52
Enterprise Value: $60,975,196
PE Ratio: -0.23
Exchange/Ticker 1: NASDAQ:LPTX
Exchange/Ticker 2: N/A
Latest Market Cap: $17,130,200
BioCentury | Feb 6, 2025
Product Development
Cardiometabolic wins among highlights in BioCentury’s latest Clinical Report
Plus readouts from Allakos, Leap, Cargo and more
BioCentury | Jan 18, 2023
Regulation
Jan. 17 Quick Takes: Moderna now in RSV vaccine regulatory race
Plus: Leap, Flame propose merger and updates from Elicio, Angion, Huadong, CARsgen and more
BioCentury | Sep 17, 2021
Product Development
ESMO Quick Takes: MacroGenics’ early proof of concept for B7-H3 ADC
Plus data from Zymeworks, Leap and Acepodia
BioCentury | Mar 19, 2020
Management Tracks
Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more
BioCentury | Jan 4, 2020
Company News
Next act for BeiGene’s tislelizumab: a Leap deal for gastric cancer
BioCentury | Oct 19, 2019
Product Development
Tracking the rise and fall of next-generation checkpoint targets for cancer
BioCentury’s analysis of next-generation checkpoint targets finds three that are gathering steam
BioCentury | Jul 11, 2019
Targets & Mechanisms
The tumor stroma rises as the newest source of immuno-oncology targets
Why companies are turning to the tumor stroma to overcome resistance to checkpoint inhibitors
BioCentury | May 4, 2018
Clinical News
Leap reports Phase I data from DKN-01 plus Keytruda arm in esophageal cancer
BioCentury | Apr 13, 2018
Clinical News
Leap reports Phase I data from monotherapy arm of esophageal cancer trial
Items per page:
1 - 10 of 20